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Abstract
 
The control of many persistent viral infections by Ag-specific cytolytic CD8
 
 
 
 T cells requires a
concurrent virus-specific CD4
 
 
 
 Th cell response. This reflects in part a requirement of activated
effector CD8
 
 
 
 T cells for paracrine IL-2 production as a growth and survival factor. In human
CMV and HIV infection, the majority of differentiated virus-specific CD8
 
 
 
 T cells notably lose
the ability to produce IL-2 but also lose expression of CD28, a costimulatory molecule. Analysis
of the fraction of memory CD8
 
 
 
 T cells that continue to express CD28 revealed these cells retain
the ability to produce IL-2. Therefore, we examined if IL-2 production by CD28
 
 
 
 CD8
 
 
 
 T cells
could be restored by introduction of a constitutively expressed CD28 gene. Expression of CD28
in CD28
 
 
 
 CD8
 
 
 
 CMV- and HIV-specific CD8
 
 
 
 T cells reconstituted the ability to produce IL-2,
which could sustain an autocrine proliferative response after Ag recognition. These results suggest
that the loss of CD28 expression during differentiation of memory/effector CD8
 
 
 
 T cells
represents a decisive step in establishing regulation of responding CD8
 
 
 
 T cells, increasing
the dependence on CD4
 
 
 
 Th for proliferation after target recognition, and has implications
for the treatment of viral disease with adoptively transferred CD8
 
 
 
 T cells.
Key words: CD8
 
  
 
T cells • CD28 • interleukin-2 • costimulation • memory response
 
Introduction
 
Acute virus infection can stimulate a vigorous CD8
 
 
 
 T cell re-
sponse, with up to 44% of the resulting CD8
 
 
 
 T cell compart-
ment committed to a single viral epitope (1). After such mas-
sive cellular expansion, the population of responding CD8
 
 
 
 T
cells must contract to restore lymphocyte homeostasis. This
cell death is a consequence of Ag clearance, cytokine with-
drawal, and Fas-FasL–mediated apoptosis, leaving a smaller
pool of memory CD8
 
 
 
 T cells (2). Some pathogens, such as
CMV and EBV, are never eliminated, and maintenance of a
high frequency of virus-specific CD8
 
 
 
 T cells is essential to
prevent viral reactivation from becoming symptomatic (1, 3).
CD8
 
 
 
 T cells can initially contain many viruses without
CD4
 
 
 
 Th cells, but long term control of persistent infection
requires CD4
 
 
 
 Th cells (4). CD4
 
 
 
 Th cells are important
for conditioning APC through interaction of molecules,
such as CD40L with CD40 (5, 6), and may directly help
activated CD8
 
 
 
 T cells by providing IL-2 as a growth
and survival factor (7). The important role of CD4
 
 
 
 Th
cells has been demonstrated in HIV infection (8). Most
individuals mount an HIV-specific CD8
 
 
 
 T cell response
that contributes significantly to the initial control of HIV
viremia (8). However, CD4
 
 
 
 HIV-specific Th cells are
selectively eliminated by direct infection (9), and HIV-
specific CD8
 
 
 
 T cells are ultimately incapable of containing
the virus (8). By contrast, the small subset of infected indi-
viduals that do retain a strong HIV-specific CD4
 
 
 
 Th
cell response maintain a stronger functional CD8
 
 
 
 T cell
response and improved control of the virus (10).
CD28 is an important costimulatory molecule for the
generation of CD4
 
 
 
 and CD8
 
 
 
 T cell responses. CD28
interacts with CD80/86 expressed by APC and, in con-
junction with a TCR signal, results in tighter formation
of the immunological synapse, increased expression of the
antiapoptotic protein BcL-X
 
L
 
, enhanced transcription and
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stability of IL-2 mRNA, and increased IL-2 production
(11–14). In humans, CD28 is expressed on all naive T cells
and on memory CD4
 
 
 
 Th cells. In contrast, CD28 expres-
sion is lost in a subset of human CD8
 
 
 
 T cells, and this
subset exhibits reduced proliferation after anti-CD3 stimu-
lation (15). CD28
 
  
 
CD8
 
 
 
 T cells are increased in the el-
derly (16) and in the CD8
 
 
 
 memory T cell pool specific for
persistent viruses, such as CMV and EBV (1, 3). The loss of
CD28 is most pronounced in HIV-specific CD8
 
 
 
 T cells,
of which 
 
 
 
90% can be CD28
 
 
 
, potentially due to contin-
uous Ag stimulation (17).
We have examined the functional consequences of the
loss of CD28 on virus-specific CD8
 
 
 
 T cells derived from
healthy individuals with chronic infection. CD28
 
 
 
 and
CD28
 
 
 
 CD8
 
 
 
 T cells were evaluated to determine if the
observed differences reflected a multitude of changes for
which loss of CD28 expression served as a marker, or if
these functions could be restored by reexpression of CD28.
The results demonstrated that loss of CD28 expression cor-
relates with the inability to produce IL-2 and proliferate af-
ter activation by APC. These functions could be reconsti-
tuted by reexpressing an intact signaling CD28 molecule by
introduction of the gene under a constitutive promoter.
 
Materials and Methods
 
Cell Lines.
 
B lymphoblastoid cells (LCL) and TAP-deficient,
HLA A*0201 T2 cells were maintained in media with 10% FCS.
The retroviral packaging cell line Phoenix-GALV was established
by transfecting Phoenix GP cells (provided by Dr. G. Nolan,
Stanford University, Stanford, CA) with the plasmid pMOV-
GaLV Seato env (provided by Dr. A.D. Miller, Fred Hutchinson
Cancer Research Center).
 
Analysis of Cell Surface Receptor Expression.
 
PBMCs were iso-
lated from 38 healthy HLA A*0201
 
 
 
 donors and stained with an
HLA A*0201 PE-labeled tetramer containing the CMV
 
pp65/495–503
 
epitope NLVPMVATV, 
 
 
 
CD8-FITC (Becton Dickinson), and
 
 
 
CD28-Cy (PharMingen). Expression of CD28 on transduced T
cell clones was evaluated by staining 5 
 
 
 
 10
 
5
 
 T cells with
 
 
 
CD28-PE (Becton Dickinson). All samples were examined on a
FACScan™ (Becton Dickinson).
 
Intracellular Cytokine Staining.
 
CD8
 
 
 
 T cells were enriched
from PBMCs of donors displaying high numbers of tetramer-
binding (tet
 
 
 
) T cells with CD8
 
 
 
 Rosette Sep (StemCell Tech-
nologies). 2 
 
 
 
 10
 
6
 
 enriched CD8
 
 
 
 T cells were incubated for 7 h
with 5 
 
 
 
 10
 
5
 
 T2 cells alone or pulsed with 10 
 
 
 
M CMV
 
pp65/495–503
 
peptide in the presence of 10 
 
 
 
g/ml 
 
 
 
CD49d mAb (Becton
Dickinson). 10 
 
 
 
g/ml brefeldin A (Sigma-Aldrich) was then
added for 5 h of incubation.
CD28
 
 
 
 CD8
 
 
 
 T cells were isolated from PBMCs, transduced
with a retroviral vector encoding CD28, and selected for CD28
expression. 5 
 
 
 
 10
 
3
 
 parental and CD28-transduced CD8
 
 
 
 T cells
were plated in a 96-well plate previously coated for 12 h at 4
 
 
 
C
with 
 
 
 
CD3 mAb (10 ng/ml) or with both 
 
 
 
CD3 mAb (10 ng/
ml) and 
 
 
 
CD28 mAb (10 
 
 
 
g/ml). After 6 h, brefeldin A was
added, and the cells were incubated for 5 h. Parental and CD28-
transduced CD28
 
 
 
 CD8
 
  
 
T cells were also stimulated with 10
ng/ml PMA (Sigma-Aldrich) and 1 
 
 
 
g/ml ionomycin (Sigma)
for 5 h followed by the addition of brefeldin A for 2 h. Samples
were permeabilized and stained with 
 
 
 
IL-2–APC (PharMingen),
 
 
 
CD8-PerCP (Becton Dickinson), and 
 
 
 
CD28-PE and analyzed
by flow cytometry.
 
Generation of Human Ag-specific CD8
 
 
 
 T Cells.
 
The CD8
 
 
 
CMV-specific T cell clones MT-2 and MT-3 were generated by
sorting tet
 
 
 
 CD8
 
 
 
 T cells specific for the pp65
 
495–503
 
 epitope and
cloning at 0.3 cells/well. HIV-specific CD8
 
 
 
 T cell clones SM-
28A2 and TL-52-H8 were generated from HIV seropositive do-
nors and recognized the HIV
 
gag/20–28
 
 epitope RLRPGGKKK pre-
sented by HLA A*0301(18).
 
Proliferation Assays.
 
Responder CD8
 
 
 
 T cells were isolated
from PBMCs by positive selection (Miltenyi) and FACS
 
®
 
-sorted
to achieve 
 
 
 
99% purity. An aliquot was also depleted of CD28
 
 
 
CD8
 
 
 
 T cells by sorting for CD28
 
  
 
CD8
 
 
 
 T cells. Mitomycin C
(Sigma-Aldrich)–treated stimulator T2 cells were pulsed with 100
ng/ml of CMV
 
pp65/495–503
 
, washed, and plated at 5 
 
 
 
 10
 
4
 
 cells/
well in 96-well plates. 2 
 
 
 
 10
 
5
 
 responder T cells were added to
triplicate wells. 10 
 
 
 
g/ml CTLA-4–Ig fusion protein (provided
by Dr. George Georges, Fred Hutchinson Cancer Research Cen-
ter) or 5 
 
 
 
g/ml anti–IL-2 receptor 
 
 
 
 mAb (R&D Systems) was
added to selected wells at culture initiation. Parental and CD28-
transduced HIV-specific CTL clones were stimulated with mito-
mycin C–treated LCL pulsed with 20 ng/ml HIV
 
gag/20–28
 
 peptide.
IL-2 (10 U/ml) was added to selected wells. Cultures were pulsed
with 1 
 
 
 
Ci 
 
3
 
[H]TdR for the final 18 h of a 90-h assay.
For the assessment of Ag-driven T cell expansion, parental and
CD28-transduced CMV-specific T cell clones were plated at 2  
106 cells/well in a 24-well plate with 2   106 mitomycin C–treated
T2 cells pulsed with 100 ng/ml of CMVpp65/495–503 peptide. After
5 d of culture, T cells were counted by trypan blue dye exclusion.
In some experiments, parental and CD28-transduced T cells were
labeled with CFSE before stimulation. CTLs were washed with
PBS and resuspended at 107 cells/ml in PBS. CFSE was added to a
final concentration of 20  M, and cells were mixed and incubated
at 23 C for 10 min. Labeling was quenched by the addition of 10%
FCS, and the cells were washed and resuspended in media contain-
ing 10% FCS. 106 CFSE-labeled CTLs were mixed with 106 mito-
mycin C–treated T2 cells pulsed with pp65495–503 peptide (100 nM)
and incubated at 37 C for 3 d. CFSE dilution was analyzed on a
FACSCalibur flow cytometer.
Construction of CD28 and CD28 Mutant Retroviral Vectors.
RNA was isolated from CD4  T cells using Qiagen RNAeasy
(QIAGEN) and reverse transcribed into cDNA by oligo-dt15
primers (Roche) and M-MLV reverse transcriptase (GIBCO
BRL). The full-length CD28 cDNA was amplified by PCR with
unique 5  and 3  primers. A point mutation of the tyrosine at po-
sition 200 to phenylalanine was introduced into the CD28 cDNA
by PCR with a codon-modified 3  primer. PCR products were
ligated into the Zero Blunt Topo cloning vector (Invitrogen) and
sequenced. The confirmed CD28 and CD28 mutant cDNAs
were cloned into pLZRSBMN (provided by Dr. G. Nolan, Stan-
ford University, Stanford, CA) downstream of the viral 5  LTR,
transfected into Phoenix GALV cells, and supernatant was har-
vested from puromycin-resistant cells.
Transduction of T Cells. CD28  CD8  T cells were purified
from PBMCs by immunomagnetic depletion of CD4  CD19 ,
CD14 , CD56 , and CD28  T cells. The purity of the remain-
ing CD28  CD8  T cells was  99% as assessed by staining with
 CD8-FITC (Becton Dickinson) and  CD28-Cy (PharMingen).
Polyclonal CD28 CD8 , T cells and CMV- or HIV-specific
CD8  clones were stimulated with  CD3 mAb (30 ng/ml) as de-
scribed (18), harvested 1 d later, and resuspended in phosphate-
deficient media (GIBCO BRL) with 10% human serum and 50
U/ml IL-2. On day 2, cells were washed, resuspended in retrovi-T
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ral supernatant with 50 U/ml IL-2 and 8  g/ml polybrene, spun
at 1,000 g for 1 h at 32 C, and incubated for 23 h. T cells were
then washed, cultured in media containing 50 U IL-2/ml, and
restimulated every 14 d.
Cytotoxicity Assays. Parental and CD28-transduced HIV-spe-
cific CTLs were assayed in a chromium release assay with HLA
A*0301  LCL target cells infected with a vaccinia recombinant vi-
rus expressing either HIVgag or, as a control, expressing CMVpp65.
IL-2 Production. IL-2 production was assessed after stimula-
tion with HLA-matched LCL pulsed for 4 h with either 20 ng
CMVpp65/495–503 or HIVgag/20–28 peptide. Responder cells (2   105
cells/well) and stimulator cells (105/well) were added to 96-well
plates. CTLA-4–Ig (10  g/ml) was added to selected wells, su-
pernatants were harvested after 36 h, and IL-2 production was
analyzed by ELISA (R&D Systems).
Results
CD28 Expression of CMV pp65-specific CD8  T cells in
Healthy Donors. An HLA-A*0201 tetramer was used to
determine the frequency and phenotype of CD8  T cells
reacting to the CMVpp65 /495–503 epitope in healthy donors.
A mean of 1.27% (range 0.2–6.0%) of all CD8bright T cells
were tet  in 19 subjects with detectable tet  cells. CD28
expression by the tet  CD8  T cells was assessed in seven
of the donors, and in five of the seven the majority of tet 
CD8bright T cells were CD28  (Fig. 1 A). The average per-
centage of CD28  T cells in the CD8  tet  population for
the seven donors was 60.7% (range 11–91%).
CD28  and CD28  Ag-specific CD8  T Cells Are
Functionally Distinct. Since CD28 engagement can mod-
ify effector functions, we evaluated if the loss of CD28 ex-
pression was associated with changes in CD8  T cell func-
tion. CD8  T cells were purified from peripheral blood,
stimulated with CD80/86-expressing APC pulsed with the
CMVpp65 peptide, and IFN-  and IL-2 production by the
CD28  and CD28  subsets was assessed by intracellular
staining. Unstimulated CD28  or CD28  CD8  T cells did
not express either IFN-  or IL-2 ( 0.05%) (Fig. 1 B). Af-
ter peptide stimulation, IFN-  production was detected in
both the CD28  and CD28  CD8  T cell populations, but
IL-2 production was only observed in CD28  CD8  T
cells and only in those that also produced IFN-  (Fig. 1 B).
IL-2 produced by CD28  CD8  T cells after target rec-
ognition might serve as an autocrine growth factor and
provide this subset with the ability to sustain a proliferative
response. Incubation of purified CD8  T cells with APC
Figure 1. IL-2 production is confined to
the subset of CMVpp65-specific CD28 
CD8  T cells. (A) CD28 staining of tet 
CD8bright T cells from two representative
donors. The percentage of T cells in each
quadrant is indicated. (B) Freshly isolated
CD8  T cells were stimulated with either T2
cells or peptide-pulsed T2 cells. Cells were
gated to identify CD28  CD8  and CD28 
CD8  T cells and assessed for cytokine
production. Values indicate the percentage
of cells in each quadrant producing IFN- 
or IL-2.T
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pulsed with 100 ng of CMVpp65/495–503 peptide elicited a
strong proliferative response with a stimulation index of
22.3 (Fig. 2). Since it was not possible to isolate sufficient
CD28  tet  cells for direct analysis, the contribution of the
CD28  population to the proliferative response was as-
sessed by blocking and depletion studies. The observed
proliferation required specific interaction between CD28
and CD80/86, since addition of CTLA-4–Ig, which has a
10-fold higher affinity for CD80/86 than does CD28 (14),
abrogated the response (Fig. 2). Addition of a mAb to IL-2
receptor   suppressed the response, indicating that IL-2
was responsible for the observed proliferation (Fig. 2). De-
pletion of CD28  T cells from the purified CD8  T cells
also abolished proliferation, but the response from the re-
maining CD28  cells was rescued by the addition of IL-2
(10 U/ml) at culture initiation (Fig. 2). These findings sug-
gest IL-2 production is essential for autocrine proliferation
and that alternative costimulatory receptors to CD28, such
as 4–1BB and LFA-1, which may be expressed on CD28 
CD8  T cells, are not sufficient for proliferation or IL-2
production under these conditions.
CD28  T Cells Transduced To Express CD28 Produce
IL-2. The ability of the CD28  subset to produce IL-2
and the inability of the CD28  CD8  subset to do so sug-
gested that failure to express and deliver signals through this
costimulatory molecule might be responsible for the loss of
function. However, CD28  CD8  T cells could also have
undergone other changes that could interfere with the abil-
Figure 2. Proliferation of CMV-specific CD8  T cells is dependent on
the CD28  CD8  subset. Purified CD8  T cells (black bars) or CD28-
depleted CD8  T cells (white bars) were stimulated with peptide-pulsed
T2 cells and proliferation assessed. Indicated wells were supplemented
with IL-2, CTLA-4–Ig, or  IL–2R-  mAb at culture initiation. All
values represent the means stimulation index of triplicate samples. The
results are representative of assays from three donors.
Figure 3. Reconstitution of CD28 restores Ag-triggered IL-2
production and T cell proliferation. (A) CD28 expression was
assessed before and after transduction of a CMV-specific CD28 
CD8  T cell clone, MT-2 with the CD28 gene. The percentage
of cells positive for both CD8 and CD28 is indicated and is
representative of five experiments. (B) IL-2 production by parental
and CD28-transduced CMV-specific CD8  T cells after Ag
stimulation. HLA-matched peptide-pulsed LCLs (CD80/86 )
were incubated with parental (  and  ) or CD28-transduced
(  and  ) CMV-specific CD8  T cell clones MT-2 (  and  )
and MT-3 (  and   ). CTLA-4–Ig was added to indicated
wells. Data points represent the means of two samples for
each clone. (C) Proliferation of CD28  parental and CD28-
transduced CD8  CMV-specific T cells. 2   106 parental
(white bar) and CD28-transduced (black bar) T cells were plated
with 2   106 mitomycin C–treated T2 cells alone or pulsed
with  100 nM of pp65495–503 peptide. IL-2 (10 U/ml) and
CTLA-4–Ig were added to selected wells. Cell growth was
assessed at day 5 by counting viable T cells.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Topp et al. Brief Definitive Report 951
ity to produce IL-2. Therefore, we expressed CD28 in
CMV-specific CD8  CTL clones and in primary CD28 
T cells using a retrovirus encoding CD28 and assessed
function. On day 12 after transduction,  90% of the trans-
duced T cells expressed both CD28 and CD8, whereas the
parental cells remained CD28  CD8  (Fig. 3 A). CD28
expression was maintained for  8 wk in CD28-transduced
T cells restimulated every 14 d (unpublished data).
Parental and CD28-transduced CTL clones were then
stimulated with HLA A*0201  LCL pulsed with 20 ng/ml
of the CMVpp65/495–503 peptide. No IL-2 production was
detected from unstimulated parental or transduced CD8 
CTLs (data not shown). Parental CD28  CD8  CTLs
stimulated with peptide-pulsed APC produced no detect-
able or very low levels of IL-2 (Fig. 3 B). In contrast, the
CD28-transduced CTLs produced substantial IL-2 after
stimulation (Fig. 3 B). Addition of CTLA-4–Ig at the initi-
ation of cultures to block CD28 engagement by CD80/86
abrogated IL-2 production by the CD28-transduced CD8 
T cells (Fig. 3 B), confirming that the IL-2 production di-
rectly resulted from expression of CD28.
We next evaluated whether IL-2 production by CD28-
transduced CD8  CMV-specific T cell clones was sufficient
for Ag-driven autocrine proliferation. Stimulation of parental
CD8  CD28  CMV-specific T cells with peptide-pulsed
APC in the absence of exogenous IL-2 led to a decrease in
cell number over 5 d in culture, although addition of IL-2
induced a sevenfold expansion (Fig. 3 C). By contrast, stim-
ulation of CD28-transduced T cells resulted in a ninefold in-
crease in cell number without addition of IL-2 (Fig. 3 C).
The proliferation of the CD28-transduced T cells was
blocked by CTLA-4–Ig, confirming the requirement for
CD28 signaling for cell expansion (Fig. 3 C). Additional ex-
periments in which both the parental and CD28-transduced
T cells were labeled with CFSE before peptide stimulation
demonstrated that the CD28-transduced T cells, but not the
CD28  parental cells, proliferated and remained viable 4 d
after stimulation (not depicted).
The restoration of IL-2 production in the T cell clones
by the expression of CD28 might be an aberration from
long term culture and not apply to CD28  T cells in the
blood. Therefore, CD28 was expressed by retroviral trans-
duction on CD28  CD8  T cells isolated from PBMC. Al-
iquots of parental and CD28-transduced T cells were then
stimulated with  CD3mAb alone, with both  CD3 and
 CD28 mAbs or with PMA and ionomycin, and evaluated
for IL-2 production by intracellular staining. No IL-2 was
detected in the parental or CD28-transduced CD8  T cells
after stimulation with  CD3mAb. However, a fraction of
the CD28-transduced but not the parental CD8  T cells
produced IL-2 after stimulation with both  CD3 and
 CD28 mAbs (Fig. 4). PMA and ionomycin stimulation,
which bypasses the requirement for TCR and costimula-
tory signals, was capable of inducing IL-2 production in
both the parental CD28  CD8  and CD28-transduced T
cells (Fig. 4). These results demonstrate that expression of
CD28 in CD28  peripheral blood T cells was sufficient to
restore IL-2 production.
Expression of CD28 in CD28  HIV-specific CD8  CTLs
Results in Ag-triggered Autocrine Proliferation. One hall-
mark of HIV infection is the loss of virus-specific CD4 
Th cells, which normally can provide IL-2 as a paracrine
growth factor for responding CD8  T cells. The majority
(70–90%) of HIV-specific CD8  T cells present during
chronic infection have lost CD28 expression (17), and this
skewing might contribute to a quantitatively inadequate re-
sponse and ineffective control of viremia. Therefore, we
evaluated if the loss of IL-2 production in HIV-specific
CD28  CD8  T cells represented a multitude of events ac-
quired during infection or if restoring CD28 expression
could reestablish the ability of these effector cells to pro-
duce sufficient IL-2 to overcome the dependence on
Figure 4. Reconstitution of CD28 expression in CD28  CD8  T cells provides costimulation for IL-2 production. CD28  CD8  T cells were
isolated from PBMCs, and an aliquot was transduced with the CD28 retrovirus. After selection,  80% of the transduced T cells expressed CD28.
CD28-transduced (bottom panels) and nontransduced (top panels) CD28  CD8  T cells were stimulated with  CD3 mAb (10 ng/ml), with both  CD3
mAb (10 ng/ml) and  CD28 mAb (10  g/ml), or with PMA and ionomycin, and then stained for intracellular IL-2.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Functional Consequences of CD28 Expression in CD8  T Cells 952
CD4  Th cells. CD28 was expressed in HIV-specific
CD28  CD8  CTL clones by retroviral transduction, and
the ability to produce IL-2 was assessed. The parental
clones did not produce IL-2 in response to Ag stimulation,
whereas the CD28-transduced T cell clones acquired this
capacity (Fig. 5 A). The IL-2 production was again abro-
gated by addition of CTLA-4–Ig (Fig. 5 A).
We next evaluated if IL-2 production by CD28-trans-
duced HIV-specific CD8  T cells was sufficient for auto-
crine proliferation after Ag stimulation. Stimulation with
peptide-pulsed APCs induced a proliferative response in
the CD28-transduced, but not the parental HIV-specific
CTL clones, and addition of CTLA-4–Ig abrogated pro-
liferation (Fig. 5 B). Supplementing IL-2 restored the
proliferative response in the presence of CTLA-4–Ig,
confirming adequate TCR triggering by the APCs and
excluding nonspecific toxicity as the reason for CTLA-4–Ig
blocking.
Introduction of a constitutive CD28 gene into CD28 
CD8  HIV-specific CTLs could potentially be explored as
an adoptive therapy strategy to improve control of viremia
in HIV-infected individuals. Therefore, we determined if
expression of CD28 in previously CD28  HIV-specific
CTLs interfered with the cytolytic function of transduced
CTLs. Parental and transduced clones demonstrated equiv-
alent lysis of targets expressing HIVgag and no nonspecific
lysis of CMVpp65-expressing targets (unpublished data).
Enhanced IL-2 Production Is Dependent On Intracellular Sig-
nals Delivered by CD28. CD28 can serve as an adhesion
molecule stabilizing the immunological synapse (11),
which might lead to a stronger TCR stimulus and en-
hanced cytokine production independent of a requirement
for CD28-mediated signaling. The intracellular portion of
CD28 contains four tyrosines, which are linked to activa-
tion of the phosphatidylinositol 3-kinase and microtubule-
associated protein kinase pathways. Individually, each of
the distal tyrosines impact the costimulatory signal for en-
hanced IL-2 production (19). Therefore, a mutated CD28
receptor was generated with a distal tyrosine changed to
phenylalanine, a mutation that reduces the costimulatory
signal for IL-2 production by  80%. Retroviral transduc-
tion with either intact or mutant CD28 led to similar levels
Figure 5. IL-2 production and proliferation of CD28-transduced HIV-specific CD8  T cell clone after Ag stimulation requires an intact CD28
costimulatory signal. (A) IL-2 production by parental and CD28-transduced HIV-specific CD8  T cells. HLA A*0301-positive LCLs pulsed with HIVgag/20–28
were incubated with the parental (  and  ) or CD28-transduced (  and  ) HIV-specific CD8  T cell clones TL-52-H8 (  and  ) and SM-28A2
(  and  ). CTLA-4–Ig was added to indicated wells. The data shown is the mean of two samples for each clone. (B) Parental TL-52-H8 (white bar) and
the CD28-transduced clone (black bar) were stimulated with HLA A*0301  LCLs alone or pulsed with the HIVgag/20–28 peptide. Selected wells were
supplemented with CTLA-4–Ig and/or IL-2. Proliferation was assessed by incorporation of [3H]-TdR. The data represents the mean [3H]-TdR
incorporation from triplicate wells and is representative of three experiments. (C) The HIV-specific CD28  CD8  T cell clone SM-28A2 was
transduced with either the intact CD28 or a mutant CD28 gene, and CD28 surface expression was assessed. (D) IL-2 production was quantified after
Ag stimulation of the parental, and CD28  and CD28 mutant-transduced SM-28A2. HLA A*0301  APCs were pulsed with the HIVgag/20–28 peptide
and incubated with either the parental (white bar), the CD28-transduced (black bar), or the CD28 mutant-transduced (gray bar) HIV-specific CD8 
T cell clone. Supernatants were harvested at 36 h, and IL-2 was measured by ELISA. The data represents the means of two experiments.T
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of CD28 expression (Fig. 5 C). The parental and the trans-
duced CTLs were stimulated with APCs pulsed with the
HLA A*0301 HIVgag/20–28 peptide, and supernatant was
harvested 36 h later. No IL-2 production could be detected
from the parental clone, whereas IL-2 was readily detected
from the CD28-transduced clone. IL-2 production was re-
duced by  80% in CD8  T cells transduced with the
CD28 mutant (Fig. 5 D) compared with the intact CD28
molecule. Thus, the capacity of CD28 to deliver a costim-
ulatory signal was essential for efficiently reconstituting IL-2
production in Ag-specific CD8  T cells.
Discussion
This paper describes a major functional consequence of
the loss of CD28 expression after maturation of CD8  T
cells from naive cells to Ag-experienced memory/effector
T cells. Only the CD28  subset of CMVpp65-specific
CD8  T cells, which represent a minority of the memory
T cells in most CMV seropositive individuals, was capable
of producing IL-2 after Ag stimulation. Reconstitution of
CD28 surface expression in primary CD28  CD8  T cells
and T cell clones by introduction of the gene under a con-
stitutive promoter restored the capacity for IL-2 produc-
tion after stimulation through the TCR and CD28.
Infection with herpes viruses results in virus persis-
tence, requiring maintenance of a strong specific CD8  T
cell response to contain the virus and prevent progressive
infection (20). The memory/effector CD8  T cell popula-
tion that provides protection is comprised of phenotypically
diverse subsets of cells. We chose to study the consequences
of CD28 expression and signaling in CMV-specific CD8 
T cells, since there is a major response to an epitope of
CMVpp65 in HLA A*0201 individuals which permits di-
rect isolation of Ag-specific CD8  T cells with tetramers
(3). In our study, CD8  T cells from A*0201  individuals
specific for this CMVpp65/495–503 epitope represented on
average 1.27% of the CD8bright T cell population, and in
this CMV-reactive population the majority of CD8  T
cells were CD28  (on average 61%), consistent with pre-
vious reports (3).
CD28 expression is not invariant by CD8  T cells. Na-
ive CD8  T cells express CD28 and can produce IL-2 after
physiologic interaction with an APC. As we have shown,
this ability to produce IL-2 remains intact for the subset of
memory CD8  T cells that retain CD28 expression. How-
ever, the CD28  CD8  subset can only produce significant
amounts of IL-2 if an extremely strong signal is delivered
through cross-linking of the TCR with anti-CD3 antibod-
ies or treatment with PMA and ionomycin (21). This re-
sponse to such nonphysiologic stimuli implies that the
inability of CD28  CD8  T cells to produce IL-2 in re-
sponse to Ag is not due to chromosomal inaccessibility of
the IL-2 gene and that production of limited amounts of
IL-2 might also occur in vivo under special stimulation
conditions. There are a large number of costimulatory mol-
ecules, including CD2, CD27, 41BB, and LFA-1, that can
deliver signals which enhance the strength of the TCR sig-
nal, but the most potent costimulatory signal for IL-2 pro-
duction is delivered via CD28. Therefore, we questioned if
restoring CD28 expression would be sufficient to reconsti-
tute the ability of CD28  CD8  T cells to produce IL-2 in
response to Ag. Remarkably, the loss of expression of
CD28 appeared to be the only critical blockade to IL-2
production by CD28  CD8  T cells. Reconstitution of
IL-2 production required CD28 to function as a signaling
molecule and not just an adhesion molecule, since expres-
sion of CD28 with a point mutation of a tyrosine residue in
the signaling domain of the cytoplasmic tail failed to restore
the ability to produce IL-2.
Why should human Ag-specific CD8  T cells specifi-
cally down-regulate the expression of CD28 and therefore
lose the capacity to produce IL-2? One possibility is that
this contributes to regulating the size of the Ag-specific
CD8  T cell response. The magnitude of the CD8  re-
sponse after acute infections can be enormous, representing
 50% of all CD8  T cells (1), and it is essential that these
expanded populations be regulated and ultimately contract
after Ag clearance to maintain lymphoid homeostasis. Phe-
notypic analysis of EBV-specific CD8  T cells during the
peak of a primary EBV response has shown that up to 90%
have lost CD28 expression (1, 17). Since IL-2 is a potent
growth and survival factor during the acute response (7),
the loss of endogenous IL-2 production by CD28  CD8 
Ag-specific T cells should make these cells incapable of au-
tonomously sustaining the response after target recognition.
Thus, continued expansion of CD8  T cells that have be-
come CD28  during the acute response may be regulated
by the requirement for sufficient Ag and inflammation to
attract APCs and responding CD4  Th cells that can pro-
vide paracrine IL-2. The loss of CD28 expression also re-
sults in decreased production of intracellular antiapoptotic
proteins, potentially increasing susceptibility to death from
cytokine withdrawal and thereby promoting contraction of
the response.
Teleologically, the differentiation of CD8  T cells to a
CD28  CD8  population of memory T cells dependent
on other cells to provide IL-2 may also be important for
limiting autonomous outgrowth of autoreactive CD8  T
cells. Thus, even if naive autoreactive CD8  T cells do get
triggered, the persistence of the autoantigen may drive
maturation to a CD28  CD8  phenotype, and the re-
sponse of such CD28  CD8  T cells would not be main-
tained unless there were a concurrent loss of tolerance in
the CD4  Th cell compartment.
It has been proposed that memory CD8  T cells can be
divided into central and peripheral compartments based on
the expression of CCR7, which can attract T cells to lym-
phoid tissue (22). In individuals with chronic CMV, EBV,
or HIV infection, CCR7 expression is found on  10% of
all CD8  virus-specific T cells in the peripheral blood (17).
The vast majority these CCR7  CD8  T cells also express
CD28 (23). Thus, this population, which retains the ability
to produce IL-2 and expand in response to Ag in the ab-
sence of a CD4  Th cell response, might efficiently initiateT
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responses in the LN upon reexposure to Ag and replenish
effector CD8  T cells to contain the pathogen. If the
pathogen persists, a CD4  Th cell response might be essen-
tial to provide the necessary factors for more extensive ex-
pansion of the CD8  T cell response.
The observation that restoring CD28 expression corrects
the defect in IL-2 production in CD28  CD8  T cells has
implications for the treatment of HIV with adoptively
transferred virus-specific CD8  CTL. In HIV-infected in-
dividuals, the majority of Ag-specific CD8  T cells are
CD28  (17) and therefore dependent on IL-2 from exoge-
nous sources. Unfortunately, HIV-specific CD4  Th cells
are mostly eliminated early during the course of the disease
(24), which limits the host’s ability to generate and main-
tain an effective CD8  T cell response to the virus. Adop-
tively transferred autologous HIV-specific CD8  CTLs
have been shown to have transient antiviral activity and
home to sites of infection in vivo but exhibited limited in
vivo persistence (18). This likely reflects in part the absence
of IL-2 production, since in other settings the persistence
of transferred Ag-specific CD8  cells can be prolonged by
either the presence of an endogenous Ag-specific CD4 
Th cell response (25), the coadministration of Ag-specific
CD4  Th cells (26), or the administration of IL-2 (27). As
HIV-infected CD4  Th cells and macrophages express
CD80/86 (28, 29), reconstituting CD28 in HIV-specific
CD28  CD8  T cells before cell administration might pro-
mote in vivo proliferation and persistence of the transferred
CD8  CTLs after target recognition, which should im-
prove antiviral activity. Additionally, transfer of CD28 
CD8  CTLs may facilitate structured treatment interrup-
tions in patients on antiretroviral therapy (30), since this
might establish an effector response that is not dependent
on induction of a CD4  response to HIV to promote ef-
fective CD8  control of the resulting viremia (10, 24).
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